PDE5 inhibitors, including sildenafil, tadalafil and vardenafil, are effective in decreasing PAP and pulmonary vascular remodeling, specifically in group 1 PAH [168,169]. The gene discussed is PDE5A; the disease is pulmonary arterial hypertension.